CORONAVIRUS DISEASE 2019 AND MUCORMYCOSIS A GLOBAL THREAT: A SYSTEMIC REVIEW

BIKASH BISWAS; INDRANI PRAMANIK; SANJUKTA MANDAL; POULAMY SINGHA ROY

doi:10.22159/ajpcr.2021.v14i8.42262

Authors

BIKASH BISWAS Department of Case Taking and Repertory, Mahesh Bhattacharyya Homoeopathic Medical College and Hospital, Howrah, West Bengal, India.
INDRANI PRAMANIK Department of Physiology and Biochemistry, Mahesh Bhattacharyya Homoeopathic Medical College and Hospital, Howrah, West Bengal, India.
SANJUKTA MANDAL Department of Materia Medica, Mahesh Bhattacharyya Homoeopathic Medical College and Hospital, Howrah, West Bengal, India.
POULAMY SINGHA ROY Department of Materia Medica, Mahesh Bhattacharyya Homoeopathic Medical College and Hospital, Howrah, West Bengal, India.

DOI:

https://doi.org/10.22159/ajpcr.2021.v14i8.42262

Keywords:

Coronavirus disease 2019, Mucormycosis, Comorbidities, Diabetes mellitus

Abstract

Objectives: According to the recent studies, it is seen that coronavirus disease 2019 (COVID-19) infection is associated with many bacterial and fungal infections. In case of COVID-19 patients, diabetes mellitus (DM) and hypertension (HTN) are the prime risk factors and during the course of treatment, patients develop secondary fungal infections like mucormycosis. We conducted a systemic review of the present scenario and tried to evaluate the association of mucormycosis with COVID-19.

Methods: We searched articles related to the COVID-19 associated mucormycosis, in PubMed, IndMed, and Cochrane Library. We conducted a meta-analysis on the basis of systemically reviewed all articles which reported COVID-19 associated with mucormycosis. We analyzed comorbidity, treatment, and outcome of patients in association with COVID-19 and mucormycosis.

Results: We found a total of 196 articles based on mucormycosis, out of which only 25 were selected on the basis of our inclusion and exclusion criteria. 71 cases were found and most of the cases were from India and USA. We also found that it was more prevalent among male patients and patients with DM, and in association with HTN.

Conclusion: It is seen from the studies that patients already suffering from DM and HTN when infected with coronavirus are most likely to develop mucormycosis. Treatment of latent DM, prediabetic patients, conversely, that efforts to diagnose, detect, and treat DM may have a beneficial influence in the treatment of secondary fungal infections like mucormycosis. Finding out all the cases of DM and treatment of DM can carry out an advantageous effect in all patients suffering from COVID-19.

Downloads

Download data is not yet available.

Author Biographies

INDRANI PRAMANIK, Department of Physiology and Biochemistry, Mahesh Bhattacharyya Homoeopathic Medical College and Hospital, Howrah, West Bengal, India.

Associate Professor HOD- Department of Physiology and Biochemistry, Mahesh Bhattacharyya Homoeopathic Medical College & Hospital

SANJUKTA MANDAL, Department of Materia Medica, Mahesh Bhattacharyya Homoeopathic Medical College and Hospital, Howrah, West Bengal, India.

BHMS MD, POST GRADUATE TRAINEE( 3RD YEAR), DEPARTMENT OF MATERIA MEDICA

References

Asha P, Nilam B, Patel KR, Patel NM, Patel M. Colon targeted drug delivery system. J Pharm Sci Bio Res 2011;1:37-49.

Akala EO, Elekwachi O, Chase V, Johnson H, Marjorie L, Scott K. Organic redox-initiated polymerization process for the fabrication of hydrogels for colon-specific drug delivery. Drug Dev Ind Pharm 2003;29:375-86.

Goldman AP, Williams CS, Sheng H, Lamps LW, Williams VP, Pairet M, et al. Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis 1998;19:2195-9.

Theen MJ, Namboodiri MM, Calle EE, Flandeus WD, Health CW Jr. Aspirin use and risk of fatal cancer. Cancer Res 1993;53:1322-7.

Kumar BS, Saravanakumar M, Thirumurthy R. Formulation and evaluation of celecoxib microspheres by using ethyl cellulose and eudragit S-100 in colon drugs delivery. Pharma Chem 2010;2:322-8.

Chaturvedi G, Saha RN. A review on microsphere technology and its application. Birla Inst Technol Sci 2009;1:56-8.

Katariashail, Middha A, Sandhu P, Ajay B. Microsphere. Int J Res Pharm 2011;1:1184-97.

Mazumder R, Nath LK, Haque A, Maity T, Choudhury PK, Shrestha B, et al. Formulation and in vitro evaluation of natural polymers based microspheres for colonic drug delivery. Int J Pharm Pharm Sci 2010;2:211-9.

Fatemeh A, Rudabeh V, Rassoul D. Preparation of ethylcellulose coated gelatin microspheres as a multiparticulate colonic delivery system for 5-aminosalicilic acid. Ira J Pharm Res 2004;2:81-6.

Ghodke DS, Naikwade NS. Optimization of spray drying parameters for preparation of chitosan microspheres of oxidizing pharmaceutical active. J Pharm Res 2010;3:1752-5.

Kothawade KB, Gattani SG, Surana SJ, Amrutkar JR. Colonic delivery of aceclofenac using combination of pH and time dependent polymers. Indian Drugs 2009;46:67-70.

Mastiholimath VS, Dandagi PM, Jain SS, Gadad AP, Kulkarni AR. Time and pH dependent colon specific, pulsatile delivery of theophylline for nocturnal asthma. Int J Pharm 2007;328:49-56.

Lachman L, Liberman HA, Kanig JL, Bakan JA. The Theory and Practice of Industrial Pharmacy. 3rd ed. Bombay: Varghese Publishing House; 1991. p. 67.

Nasra MA, EL-Massik MA, Nagger VF. Development of metronidazole colon-specific delivery systems. Asian J Pharm Sci 2007;2:18-28.

Anekant J, Yashwant G, Sanjay KJ. Perspectives of biodegradable natural polysaccharides for site-specific drug delivery to the colon. J Pharm Pharm Sci 2007;10:86-128.